deltatrials
Unknown PHASE1 NCT04444245

Ovarian Rejuvenation Using Platelet Rich Plasma (PRP) & Autologous Tissue Stromal Vascular Fraction (tSVF) and Cell Enriched tSVF

Re-establishment of Ovarian Hormonal Function, Delay of Menopause, or Reversal of Early Menopause With High Density (HD PRP), tSVF + PRP, or Cell Enriched tSVF + PRP by Ultrasound Guided Ovarian Injection

Sponsor: Black Tie Medical, Inc.

Updated 8 times since 2020 Last updated: Jul 18, 2022 Started: Jul 15, 2022 Primary completion: Sep 30, 2024 Completion: Aug 15, 2025

This PHASE1 trial investigates Hormone Disturbance and Ovarian Failure and is currently ongoing. Black Tie Medical, Inc. leads this study, which shows 8 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

8 versions recorded
  1. Sep 2025 — Present [monthly]

    Unknown PHASE1

    Status: Active Not RecruitingUnknown

  2. Sep 2024 — Sep 2025 [monthly]

    Active Not Recruiting PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

  4. Sep 2022 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

  5. Mar 2021 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1

Show 3 earlier versions
  1. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE1

  2. Aug 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

  3. Jul 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Black Tie Medical, Inc.
Data source: Black Tie Medical, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • Colchester, United States